Level C· Early human research exploring benefitsProspective StudyEurope PMC

Immunomodulative effects of mesenchymal stem cells derived from human embryonic stem cells in vivo and in vitro

Tan Z., Su ZY., Wu RR., Gu B., Liu YK., Zhao XL.

Prospective Study on Chronic Inflammation, Immune Modulation, published in J Zhejiang Univ Sci B (2011) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
J Zhejiang Univ Sci B (2011)
Reported sample size
—
Source database
Europe PMC
PMID
21194182
PMCID
PMC3017412
DOI
10.1631/jzus.b1000074
Citations
18

Abstract (original English)

Objective Human embryonic stem cells (hESCs) have recently been reported as an unlimited source of mesenchymal stem cells (MSCs). The present study not only provides an identical and clinically compliant MSC source derived from hESCs (hESC-MSCs), but also describes the immunomodulative effects of hESC-MSCs in vitro and in vivo for a carbon tetrachloride (CCl(4))-induced liver inflammation model. Methods Undifferentiated hESCs were treated with Rho-associated kinase (ROCK) inhibitor and induced to fibroblast-looking cells. These cells were tested for their surface markers and multilineage differentiation capability. Further more, we analyzed their immune characteristics by mixed lymphocyte reactions (MLRs) and animal experiments. Results hESC-MSCs show a homogenous fibroblastic morphology that resembles bone marrow-derived MSCs (BM-MSCs). The cell markers and differentiation potential of hESC-MSCs are also similar to those of BM-MSCs. Unlike their original cells, hESC-MSCs possess poor immunogenicity and can survive and be engrafted into a xenogenic immunocompetent environment. Conclusions The hESC-MSCs demonstrate strong inhibitory effects on lymphocyte proliferation in vitro and anti-inflammatory infiltration properties in vivo. This study offers information essential to the applications of hESC-MSC-based therapies and evidence for the therapeutic mechanisms of action.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
Cell LineMesenchymal Stem CellsAnimalsMice, Inbred BALB CHumansMiceCarbon TetrachlorideDNA PrimersAntigens, SurfaceLymphocyte Culture Test, Mixed

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research